EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti-CD38 therapy for the treatment of autoimmune neutropenia

Rebecca K. Leaf, Steven M. Holland, David B. Sykes

Blood Immunology & Cellular Therapy · 2026-10 · 100104

DOI: 10.1016/j.bict.2026.100104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Immunology & Cellular Therapy, 2026-10. Verfasst von Rebecca K. Leaf und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A 23-year-old female presented with a dental infection and neutropenia (ANC = 100 /μL). She had symptoms of fatigue, leg pain, and night sweats. She took no medications and had no significant medical history. The remainder of her CBC was normal. Laboratory testing revealed an anti-neutrophil antibody, supporting a diagnosis of autoimmune neutropenia (AiN). Her symptoms persisted and she suffered recurrent episodes of cellulitis, folliculitis, and bacteremia that required inpatient treatment.

Methods

Given the frequency of hospitalizations, we undertook a series of therapeutic trials. Sequential treatments with granulocyte colony stimulating factor (G-CSF), intravenous immunoglobulin, rituximab, mycophenolate mofetil, and fostamatinib failed to improve her neutropenia. In view of her positive antibody studies but failure to respond to rituximab, she received the anti-CD38 monoclonal antibody, daratumumab.

Results

Her ANC increased from ∼450 /μl to ∼1000 /μl, accompanied by marked improvement in her symptoms. Over 6 months, the patient’s ANC gradually declined, with recurrence of her constitutional symptoms. She subsequently received daratumumab-hyaluronidase and her ANC improved to ∼1300 /μL, again accompanied by marked symptomatic improvement.

Conclusions

Since initiating daratumumab therapy, she has required neither antibiotic treatment nor hospitalization. Importantly, the improvement in her ANC was also accompanied by improvement in symptoms and quality of life.

Zitieren

APA

Leaf, R. K., Holland, S. M., & Sykes, D. B. (2026). Anti-CD38 therapy for the treatment of autoimmune neutropenia. Blood Immunology & Cellular Therapy, 100104. https://doi.org/10.1016/j.bict.2026.100104

Vancouver

Leaf RK, Holland SM, Sykes DB. Anti-CD38 therapy for the treatment of autoimmune neutropenia. Blood Immunology & Cellular Therapy. 2026:100104. doi:10.1016/j.bict.2026.100104

BibTeX
@article{Leaf2026,
  author = {Leaf, Rebecca K. and Holland, Steven M. and Sykes, David B.},
  title = {Anti-CD38 therapy for the treatment of autoimmune neutropenia},
  journal = {Blood Immunology & Cellular Therapy},
  year = {2026},
  pages = {100104},
  doi = {10.1016/j.bict.2026.100104}
}
Kostenlos starten →